Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Jim Cramer Expects Novo Nordisk A/S (NVO) To Forecast A Good 2025
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
FierceBiotech6d
UPDATED: Trump to impose tariffs on Canada, Mexico, China; industry lobbies for medtech exemptions
President Donald Trump said his administration will install 25% tariffs on goods from Canada and Mexico, ending the largely ...
How Trump tariffs could affect weight loss drugs
Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...
devdiscourse1d
Healthcare Stocks Propel European Shares Amid Choppy Session
European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...